CN1965838A - Pharmaceutical composition containing cefpiramide and beta-lactamase inhibitor - Google Patents
Pharmaceutical composition containing cefpiramide and beta-lactamase inhibitor Download PDFInfo
- Publication number
- CN1965838A CN1965838A CN 200510048556 CN200510048556A CN1965838A CN 1965838 A CN1965838 A CN 1965838A CN 200510048556 CN200510048556 CN 200510048556 CN 200510048556 A CN200510048556 A CN 200510048556A CN 1965838 A CN1965838 A CN 1965838A
- Authority
- CN
- China
- Prior art keywords
- cefpiramide
- sodium
- beta
- lactamase
- sulbactam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 title claims description 139
- 229960005446 cefpiramide Drugs 0.000 title claims description 137
- 239000003781 beta lactamase inhibitor Substances 0.000 title claims description 19
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title claims description 19
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title description 7
- 239000003814 drug Substances 0.000 claims abstract description 24
- 102000006635 beta-lactamase Human genes 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 108090000204 Dipeptidase 1 Proteins 0.000 claims abstract description 17
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960003324 clavulanic acid Drugs 0.000 claims abstract description 15
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims abstract description 15
- 230000000844 anti-bacterial effect Effects 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 18
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 229960000373 tazobactam sodium Drugs 0.000 claims description 12
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 claims description 11
- 229910052783 alkali metal Inorganic materials 0.000 claims description 11
- -1 alkali metal salt Chemical class 0.000 claims description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 229960005256 sulbactam Drugs 0.000 claims description 9
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 9
- 241001597008 Nomeidae Species 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 6
- 229930064664 L-arginine Natural products 0.000 claims description 6
- 235000014852 L-arginine Nutrition 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 108020004256 Beta-lactamase Proteins 0.000 claims 2
- 229930186147 Cephalosporin Natural products 0.000 abstract description 7
- 229940124587 cephalosporin Drugs 0.000 abstract description 7
- 150000001780 cephalosporins Chemical class 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 230000003115 biocidal effect Effects 0.000 abstract description 4
- 239000000837 restrainer Substances 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 2
- 238000002347 injection Methods 0.000 description 46
- 239000007924 injection Substances 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 36
- 238000000034 method Methods 0.000 description 33
- 239000012467 final product Substances 0.000 description 29
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 25
- 229940038649 clavulanate potassium Drugs 0.000 description 23
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 description 21
- 229960000614 sulbactam sodium Drugs 0.000 description 21
- 229960003865 tazobactam Drugs 0.000 description 18
- 239000007788 liquid Substances 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- 239000011591 potassium Substances 0.000 description 9
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 229940086761 arginine 500 mg Drugs 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229960002417 cefoperazone sodium Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 229940087379 sodium bicarbonate 500 mg Drugs 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004142 Bartholinitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101710197992 Penicillin-binding protein PbpB Proteins 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 206010034686 Peritonsillar abscess Diseases 0.000 description 1
- 206010049592 Peritonsillitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- PRWVAPJXQCMOFT-UHFFFAOYSA-N azanium;potassium;hydroxide Chemical compound [NH4+].[OH-].[K+] PRWVAPJXQCMOFT-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940028934 tazobactam 250 mg Drugs 0.000 description 1
- 229940098271 tazobactam 500 mg Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a drug composite with cooperate antibiosis function, and relative production, wherein it comprises cephalosporin or its salt, and beta-lactamase restrainer (clavulanic acid, methmazole, etc) at 10:1-1:10 ration. Said composite has better antibiosis effect on single cephalosporin, etc.
Description
Technical field
The present invention relates to the pharmaceutical composition that a kind of cefpiramide and beta-lactamase inhibitor compatibility are formed
Background technology
Cephalosporin antibacterial and clinically be used widely, for human health plays positive role, but owing to use widely for a long time clinically, antibacterial is serious day by day to the antibiotic drug resistance problem of cephalo-type, antibacterial is to produce specific beta-lactamase (β-Lactmases) decomposes medicine to the main cause of cephalo-type antibiotics resistance, comprising the defeated enzyme of the I type cephalo bacterium that the chromosome mediation is arranged with by plasmid-mediated extended spectrum, to produce the clinical drug-resistant sexuality that the beta-lactamase antibacterial caused and dye in order to overcome, the compound preparation of development cephalosporins and beta-lactamase inhibitor has the important clinical meaning.Lactamase restrainer has sulbactam (Subactam SBT), Tazobactam Sodium (Tazobactam TAZ), clavulanic acid (Clavulanic acid) and derivant thereof etc.At present, successively the cephalosporins of listing and the compound preparation of beta-lactamase inhibitor have cefoperazone/sulbactam sodium, ceftriaxone sodium/sulbactam sodium, cefoperazone sodium/tazobactam sodium etc.
Cefpiramide (Cefpiramide) is a third generation cephalosporin by invention in the age, by anti-microbial property belong to the 4th generation cephalosporin.This product has has a broad antifungal spectrum, has good characteristics of pharmacokinetics, to the lactamase good stability, cefpiramide all has good antibacterial activity to the Gram-positive ball, simultaneously gram negative bacilli is had antibacterial activity efficiently, have the antimicrobial spectrum of perfect balance.
Cefpiramide be by with the PBP1A of penicillin-binding protein (PBP), PBP1B and PBP3 have very strong affinity, suppress the synthetic of cell wall, thus the performance bactericidal action.G+, G-bacterium are had broad spectrum antibiotic activity, especially bacillus pyocyaneus is had very strong antimicrbial power.Minimum inhibitory concentration (MIC) to bacillus pyocyaneus is 0.78-3.13 μ g/ml, is 0.39-0.78 μ g/ml to the MIC of golden Portugal Pseudomonas, and colibacillary MIC is 0.39 μ g/ml, is 0.05-6.25 μ g/ml to the MIC of Proteus.MIC80 difference 0.78 μ g/ml and 0.39 μ g/ml to dyspepsiacoccus, peptostreptococcus in the anaerobe.
When quiet notes cefpiramide 0.5g of health adult and 1.0g, blood level reached 163 μ g/ml and 264 μ g/ml respectively after 5 minutes, dropped to 10.7 μ g/ml and 17.7 μ g/ml after 24 hours respectively, and the blood level half-life is 4.5h.When quiet 1g of 1h and 2g, the blood drug level peaking when finishing that instils is respectively 215 μ g/ml and 306 μ g/ml, drops to 14.7 μ g/ml and 30.6 μ g/ml respectively behind the beginning 12h that instils.Blood level is high and lasting, but does not have cumulative bad due to the successive administration.This product distributes good in body fluid, tissue.This product is metabolism hardly in vivo, does not find the antibacterial activity metabolite in urine, the excrement.Elimination factor is the high concentration that still keeps 50 μ g/ml in the urine after 23%, 24 hour in the urine in health adult's intravenous injection 24 hours.This product is a bile excretion type medicine, so dense in the bile.The patient of renal function height obstacle, the half-life also only prolongs 1.3 times in the blood, this be since this product mainly from bile excretion, when renal dysfunction, bile excretion is able to due to the compensatory increase in the body.
Cefpiramide is used for responsive microbial following infection clinically: septicemia, burn, secondary infection such as surgical wound, pharyngolaryngitis (throat abscess) acute bronchitis, tonsillitis (peritonsillitis disease, peritonsillar abscess), chronic bronchitis, bronchiectasis (during infection), the secondary infection of chronic respiratory tract disease, pneumonia, pulmonary abscess, empyema, pyelonephritis, cystitis, prostatitis, epididymis inflammation, cholecystitis, cholangitis, peritonitis (peritonaeum pelvicum inflammation, bladder rectum depression abscess, adnexitis, intrauterine infection, pelvic inflammatory disease, the other inflammation of connective tissue in uterus, bartholinitis, brain (ridge) film inflammation, jaw arthritis, cellulitis around the jawbone.
Detailed Description Of The Invention
The object of the present invention is to provide a kind of antibacterial compound drug that suppresses beta-lactamase, do not destroyed, strengthen its curative effect again, solve antibacterial the drug-fast problem of cefpiramide by bacteriogenic beta-lactamase with the protection cefpiramide.
Another object of the present invention is to antibacterial compound drug and combined by cefpiramide (Cefpiramide) and beta-lactamase inhibitor, cefpiramide and beta-lactamase inhibitor are by active acid, and their weight ratio is 1-10: 10-1.
The antibacterial compound drug of inhibition beta-lactamase of the present invention is characterized in that by proportioning cefpiramide being mixed back administration or administration respectively with beta-lactamase inhibitor again when said combination comprises clinical use.
The antibacterial compound drug of inhibition beta-lactamase of the present invention, the alkali metal salt (comprising its hydrate) that it is characterized in that said cefpiramide, the alkali metal salt of cefpiramide is meant cefpiramide sodium, also can be other alkali metal salt or its hydrate of cefpiramide, preferred cefpiramide sodium.
The antibacterial compound drug of inhibition beta-lactamase of the present invention is characterized in that said cefpiramide can be the form that Cefpiramide Acid adds (comprising its hydrate) cosolvent.
The antibacterial compound drug of inhibition beta-lactamase of the present invention is characterized in that said cosolvent is the L-arginine, or sodium carbonate, or sodium bicarbonate.
Beta-lactamase inhibitor among the present invention is meant sulbactam (Subactam) or derivatives thereof, or clavulanic acid (Clavulanic acid) or derivatives thereof, or Tazobactam Sodium (Tazobactam) or derivatives thereof.
The antibacterial compound drug of inhibition beta-lactamase of the present invention is characterized in that said clavulanic acid derivant is the alkali metal salt of clavulanic acid, preferred clavulanate potassium.
The antibacterial compound drug of inhibition beta-lactamase of the present invention is characterized in that said sulbactam derivant is the alkali metal salt of sulbactam, preferred sulbactam sodium.
The antibacterial compound drug of inhibition beta-lactamase of the present invention is characterized in that said Tazobactam Sodium derivant is the alkali metal salt of Tazobactam Sodium, preferred sodium-tazobactam.
Technical solution of the present invention is as follows:
A kind ofly be used to prevent that cefpiramide from by the enzyme inhibitor of the beta-lactam enzyme hydrolysis deactivation that antibacterial produced, is characterized in that:
Cefpiramide and beta-lactamase inhibitor be 1-10 by a certain percentage: 10-1 fully mixes use.
Technical solution of the present invention also comprises:
Cefpiramide and a certain proportion of beta-lactamase inhibitor aseptic powder are by the content of measuring, behind the deduction moisture, after in blender, fully mixing, in the toilet, under aseptic condition, pack in the antibiotics bottle of cleaning, dry sterilization butyl rubber plug beyond the Great Wall, gland seal into.
Pharmaceutical composition of the present invention has synergetic antibacterial effect, and said composition can be used for mammiferous bacterial infection.Contained cefpiramide or its pharmaceutical salts are because of share the generation synergism with beta-lactamase inhibitor in the said composition, its activity to gram-positive cocci and gram negative bacilli greatly strengthens, expanded antimicrobial spectrum simultaneously, solve the drug resistance problem of cefpiramide effectively, enlarged clinical application range.
The present invention has following good effect:
(1) in the pharmaceutical composition of the present invention, as antibiotics is cefpiramide, it has high activity to grand coccus of gram and part gram negative bacilli, and act on simultaneously with the different piece of beta-lactamase inhibitor to pathogen, therefore can stop the resistant function of pathogen effectively, slow down drug-fast development greatly.
(2) pharmaceutical composition of the present invention has synergetic antibacterial effect simultaneously, and beta-lactamase inhibitor has strengthened the cefpiramide antibacterial activity effectively, and antibacterial range is expanded simultaneously.
(3) pharmaceutical composition of the present invention has little, the no allergy of blood vessel irritation and haemolysis, safe feature.
Experimental example 1 vivo bacteria corrosion action
Do laboratory animal with white mice, clinical isolating product enzyme antibacterial staphylococcus aureus, dust Xi Shi escherichia coli, bacillus pyocyaneus are strain subject.In quantitative inoculation of bacterial strain and nutrient broth, cultivating temperature for 37 ℃ incubated 6 hours, get bacterium liquid 0.1ml transferred species in the 10ml nutrient broth, 37 ℃ of cultivations were hatched 18 hours, make the zoogenetic infection bacterium, after the test organisms liquid inductance of amount dyes till death with the mouse peritoneal injection, can after infecting 6 hours, give cefpiramide respectively, clavulanate potassium, Tazobactam Sodium is received, sulbactam is received, cefpiramide sodium/crin is tieed up sour potassium, the cefpiramide sodium/tazobactam sodium, cefpiramide sodium/sulbactam sodium is subjected to the reagent product, observed 7 days continuously, write down each treated animal death condition, calculate median effective dose (ED50), the results are shown in Table 1.
Table 1 cefpiramide sodium/clavulanate potassium, cefpiramide sodium/tazobactam and cefpiramide sodium/sulbactam sodium are to the intravital antibacterial action of infecting mouse
| Infectious bacteria MLD (Cfu.mouse -1) | Medicine | ED50/(mgkg -1) |
| Staphylococcus aureus 3.1 * 10 5 | 2: 14: 1 CefPiramide Sodium/sulbactams of 2: 14: 1 cefpiramide sodium/tazobactams of cefpiramide CefPiramide Sodium/potassium clavulanate 2: 14: 1 | 7.7(5.3-10.1) 2.7(1.5-4.1) 3.1(1.8-4.6) 1.9(1.1-3.5) 2.3(1.4-3.8) 1.8(1.2-3.3) 2.4(1.3-3.5) |
| Dust Xi Shi escherichia coli 6.9 * 10 6 | 2: 14: 1 CefPiramide Sodium/sulbactams of 2: 14: 1 cefpiramide sodium/tazobactams of CefPiramide Sodium CefPiramide Sodium/potassium clavulanate 2: 14: 1 | 0.42(0.25-0.59) 0.8(0.53-1.20) 0.92(0.84-1.27) 0.57(0.32-0.85) 0.68(0.49-0.96) 0.59(0.34-0.86) 0.69(0.47-0.98) |
| Bacillus pyocyaneus 5.7 * 10 4 | 2: 14: 1 CefPiramide Sodium/sulbactams of 2: 14: 1 cefpiramide sodium/tazobactams of CefPiramide Sodium CefPiramide Sodium/clavulanic acid 2: 14: 1 | 40.5(32.3-51.8) 11.9(8.8-14.7) 17.2(13.7-22.1) 8.2(6.7-10.0) 10.5(7.8-13.9) 8.1(6.8-10.1) 10.3(7.9-13.89) |
Experimental example 2 animal acute toxicity tests
Test animal is a white mice, and is oral respectively to being received (2: 1) with cefpiramide sodium/clavulanate potassium (2: 1), cefpiramide sodium/tazobactam (4: 1) and cefpiramide sodium/sulbactam, observes and also measures LD
50
The result shows, two medicine LD
50All above 10000mgkg
-1
The test of experimental example 3 hemolytics
Use male rabbit, hemolytic test requirements document and method are carried out the hemolytic test of cefpiramide sodium/clavulanate potassium (2: 1), cefpiramide sodium/tazobactam (4: 1) and cefpiramide sodium/sulbactam sodium (2: 1) routinely.The results are shown in Table 2.
The hemolytic result of the test of table 2 cefpiramide sodium/clavulanic acid (2: 1), cefpiramide sodium/tazobactam (4: 1) and cefpiramide sodium/sulbactam sodium (2: 1)
| Experiment liquid | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Cefpiramide sodium/clavulanic acid normal saline red blood cell suspension | 0.1 2.4 2.5 | 0.2 2.3 2.5 | 0.3 2.2 2.5 | 0.4 2.1 2.5 | 0.5 2.0 2.5 | - 2.5 2.5 | -distilled water 2.5 |
| The result | - | - | - | - | - | - | + |
| Cefpiramide sodium/tazobactam normal saline red blood cell suspension | 0.1 2.4 2.5 | 0.2 2.3 2.5 | 0.3 2.2 2.5 | 0.4 2.1 2.5 | 0.5 2.0 2.5 | - 2.5 2.5 | -distilled water 2.5 |
| The result | - | - | - | - | - | - | + |
| Cefpiramide sodium/sulbactam sodium normal saline red blood cell suspension | 0.1 2.4 2.5 | 0.2 2.3 2.5 | 0.3 2.2 2.5 | 0.4 2.1 2.5 | 0.5 2.0 2.5 | - 2.5 2.5 | -distilled water 2.5 |
| The result | - | - | - | - | - | - | + |
Annotate: "-" represents not haemolysis; "+" expression haemolysis.
The test of experimental example 4 local irritations
Laboratory animal is a rabbit, according to a conventional method medicine cefpiramide sodium/clavulanate potassium (2: 1), cefpiramide sodium/tazobactam (4: 1) and cefpiramide sodium/sulbactam sodium (2: 1) is instiled by ear vein respectively and the quadriceps femoris injection.As a result, three medicine intravenous injection 100ml, quadriceps femoris injection 2ml fails to observe the congested and edema phenomenon of injection portion after 24 hours; Tissue slice is not seen obvious change.
The test of experimental example 5 systemic anaphylaxis
Experimental animal is a Cavia porcellus, with medicine cefpiramide sodium/clavulanate potassium (2: 1), cefpiramide sodium/tazobactam (4: 1) and cefpiramide sodium/sulbactam sodium (2: 1), makes positive control with Ovum Gallus domesticus album, respectively through lumbar injection by rectangular method.Experimental result shows that the Cavia porcellus of administration group all do not have obvious anaphylaxis, and the matched group anaphylaxis is obvious after administration is attacked.
From the test the result as can be known, use in conjunction cefpiramide and beta-lactamase inhibitor have synergism to multiple gram positive bacteria and negative infectious bacteria.
Therefore, bactericidal composition of the present invention not only can be used for preventing or treating the infection that various infectious bacterias cause separately, and can be used for prevention or treatment has a plurality of microbial infection, especially the infection that gram positive bacteria and above-mentioned other Pseudomonas are caused.
The present invention will describe preparation of drug combination in detail below with embodiment, but the present invention is not by these
Embodiment limits.
Embodiments of the invention are as follows:
Embodiment 1 mixes cefpiramide sodium 250mg (by cefpiramide) with clavulanate potassium 250mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 2 mixes cefpiramide sodium 250mg (by cefpiramide) with clavulanate potassium 62.5mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 3 mixes cefpiramide sodium 250mg (by cefpiramide) with clavulanate potassium 31.25mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 4 mixes cefpiramide sodium 500mg (by cefpiramide) with clavulanate potassium 500mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 5 mixes cefpiramide sodium 500mg (by cefpiramide) with clavulanate potassium 250mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 6 mixes cefpiramide sodium 500mg (by cefpiramide) with clavulanate potassium 100mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 7 mixes cefpiramide potassium 500mg (by cefpiramide) with sodium-tazobactam 1000mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 8 mixes cefpiramide sodium 500mg (by cefpiramide) with Tazobactam Sodium 62.5mg, get final product by the preparation of injection procedure operation.
Embodiment 9 mixes cefpiramide hydrate 500mg (by cefpiramide) with sulbactam sodium 1000mg (by active acid) and L-arginine 500mg, get final product by the preparation of injection procedure operation.
Embodiment 10 mixes cefpiramide sodium 600mg (by cefpiramide) with sulbactam sodium 100mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 11 mixes Cefpiramide sodium hydrate 700mg (by cefpiramide) with sulbactam sodium 200mg (by active acid), get final product by the operation of preparation of injection journey.
Embodiment 12 mixes cefpiramide potassium 800mg (by cefpiramide) with clavulanate potassium 100mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 13 mixes cefpiramide potassium 800mg (by cefpiramide) with sodium-tazobactam 100mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 14 mixes cefpiramide potassium (by cefpiramide) 900mg with clavulanate potassium 300mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 15 mixes Cefpiramide Acid (by cefpiramide) 900mg with sulbactam sodium 100mg (by active acid) and L-arginine 500mg, get final product by the preparation of injection procedure operation.
Embodiment 16 mixes cefpiramide potassium 1000mg (by cefpiramide) with clavulanate potassium 2000mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 17 mixes cefpiramide sodium 1000mg with clavulanate potassium 1000mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 18 mixes cefpiramide potassium 1000mg (by cefpiramide) with clavulanate potassium 200mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 19 mixes Cefpiramide sodium hydrate 1000mg (by cefpiramide) with clavulanate potassium 100mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 20 mixes cefpiramide potassium hydrate 1000mg (by cefpiramide) with sodium-tazobactam 1000mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 21 mixes cefpiramide hydrate 1000mg (by cefpiramide) with sodium-tazobactam 500mg (by active acid) and sodium bicarbonate 500mg, get final product by the preparation of injection procedure operation.
Embodiment 22 mixes cephalo ammonium potassium hydrate (by a cefpiramide) 1000mg with sodium-tazobactam 250mg (by active acid) and L-arginine 500mg, get final product by the preparation of injection procedure operation.
Embodiment 23 mixes cefpiramide potassium (by cefpiramide) 1000mg with sodium-tazobactam 100mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 24 mixes cefpiramide 1000mg with sulbactam sodium 1000mg (by active acid) and L-arginine 500mg, get final product by the preparation of injection procedure operation.
Embodiment 25 mixes cefpiramide sodium 1500mg (by cefpiramide) with clavulanic acid 750mg, get final product by the preparation of injection procedure operation.
Embodiment 26 mixes cefpiramide potassium 2000mg (by cefpiramide) with sulbactam sodium 1000mg (by active acid), get final product by the preparation of injection procedure operation.
Embodiment 27 is dissolved in 1 of cefpiramide sodium for injection (1.0g/ props up) and injection clavulanate potassium (0.5g/ props up) in same 100 milliliters of glucose infusion liquids, gives quiet of sensitive organism infected patient.
Embodiment 28 is dissolved in 1 of cefpiramide sodium for injection (1.0g/ props up) and injection clavulanate potassium (0.25g/ props up) in same 100 milliliters of glucose infusion liquids, gives quiet of sensitive organism infected patient.
Embodiment 29 is dissolved in 1 of cefpiramide sodium for injection (1.0g/ props up) and injection sodium-tazobactam (0.5g/ props up) in same 100 milliliters of glucose infusion liquids, gives quiet of sensitive organism infected patient.
Embodiment 30 is dissolved in 1 of cefpiramide sodium for injection (1.0g/ props up) and injection sodium-tazobactam (0.25g/ props up) in same 100 milliliters of glucose infusion liquids, gives quiet of sensitive organism infected patient.
Embodiment 31 is dissolved in 1 of cefpiramide sodium for injection (1.0g/ props up) and injection sulbactam sodium (0.5g/ props up) in same 250 milliliters of glucose infusion liquids, gives quiet of sensitive organism infected patient.
Embodiment 32 is dissolved in 2 of cefpiramide sodium for injection (0.5g/ props up) and injection sulbactam sodium (1.0g/ props up) in same 250 milliliters of glucose infusion liquids, gives quiet of sensitive organism infected patient.
Embodiment 33 mixes cefpiramide 250mg with clavulanic acid 125mg (by active acid), get final product by the preparation of injection procedure operation, and its prescription and technology are as follows:
Prescription: cefpiramide 250mg
Sodium bicarbonate 250mg
Clavulanate potassium 125mg
Mannitol 150mg
Water for injection 5ml
Preparation technology: under aseptic technique, get the cefpiramide, sodium bicarbonate of recipe quantity and clavulanate potassium and add water for injection to be stirred to medicinal liquid clear and bright; Add mannitol, the dissolving back adds the medical active carbon decoloring, filter, and again through the filtering with microporous membrane degerming, bottling, lyophilizing, promptly.
Embodiment 34 mixes cefpiramide sodium 500mg with sodium-tazobactam 125mg, get final product by the preparation of injection procedure operation, and its prescription and technology are as follows:
Prescription: cefpiramide sodium 500mg
Sodium-tazobactam 125mg
Mannitol 150mg
Water for injection 5ml
Preparation technology: under aseptic technique, get the cefpiramide sodium of recipe quantity and sodium-tazobactam and add water for injection to be stirred to medicinal liquid clear and bright; Add mannitol, the dissolving back adds the medical active carbon decoloring, filter, and again through the filtering with microporous membrane degerming, bottling, lyophilizing, promptly.
Embodiment 35 mixes cefpiramide hydrate 500mg with sulbactam sodium 250mg (by active acid), get final product by the preparation of injection procedure operation, and its prescription and technology are as follows:
Prescription: cefpiramide 500mg
Sulbactam sodium 250mg
Sodium bicarbonate 500mg
Mannitol 150mg
Water for injection 5ml
Preparation technology: under aseptic technique, get the cefpiramide, sodium bicarbonate of recipe quantity and sulbactam sodium and add water for injection to be stirred to medicinal liquid clear and bright; Add mannitol, the dissolving back adds the medical active carbon decoloring, filter, and again through the filtering with microporous membrane degerming, bottling, lyophilizing, promptly.
In an embodiment of the present invention, cefpiramide and beta-lactamase inhibitor can provide the suitable amount of effective dose to exist, and described effective dose depends on the reactive compound of given treatment and the pharmaceutical properties of preparation.
Claims (7)
1. bactericidal composition that suppresses beta-lactamase, it is characterized in that by cefpiramide (Cefpiramide) and beta-lactamase inhibitor respectively by active acid weight ratio 1-10: 10-1 combines.
2. according to the antibacterial compound drug of the described inhibition beta-lactamase of claim 1, it is characterized in that by proportioning cefpiramide being mixed back administration or administration respectively with beta-lactamase inhibitor again when said combination comprises clinical use.
3. according to the antibacterial compound drug of claim 1 or 2 described inhibition beta-lactamases, it is characterized in that the alkali metal salt (comprising its hydrate) of said cefpiramide or the form that its free acid adds (comprising its hydrate) cosolvent.
4. according to the antibacterial compound drug of the described inhibition beta-lactamase of claim 3, the alkali metal salt that it is characterized in that said cefpiramide is cefpiramide sodium (Cefpiramide sodium).
5. according to the antibacterial compound drug of the described inhibition beta-lactamase of claim 3, it is characterized in that said cosolvent is the L-arginine, or sodium carbonate, or sodium bicarbonate.
6. according to the antibacterial compound drug of claim 1 or 2 described inhibition beta-lactamases, it is characterized in that said beta-lactamase inhibitor is the clavulanic acid or derivatives thereof, or the sulbactam or derivatives thereof, or the Tazobactam Sodium or derivatives thereof.
7. according to the antibacterial compound drug of the described inhibition beta-lactamase of claim 6, it is characterized in that said clavulanic acid derivant is the alkali metal salt of clavulanic acid, said sulbactam derivant is the alkali metal salt of sulbactam, and said Tazobactam Sodium derivant is the alkali metal salt of Tazobactam Sodium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510048556 CN1965838A (en) | 2005-11-17 | 2005-11-17 | Pharmaceutical composition containing cefpiramide and beta-lactamase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510048556 CN1965838A (en) | 2005-11-17 | 2005-11-17 | Pharmaceutical composition containing cefpiramide and beta-lactamase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1965838A true CN1965838A (en) | 2007-05-23 |
Family
ID=38074931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510048556 Pending CN1965838A (en) | 2005-11-17 | 2005-11-17 | Pharmaceutical composition containing cefpiramide and beta-lactamase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1965838A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101838276A (en) * | 2010-05-17 | 2010-09-22 | 胡梨芳 | Cefpiramide sodium hydrate and preparation method and application thereof |
| CN101966152A (en) * | 2010-10-29 | 2011-02-09 | 广州白云山天心制药股份有限公司 | Cefpiramide composite |
| CN101849947B (en) * | 2010-02-25 | 2012-07-04 | 深圳市新泰医药有限公司 | Composition of cefazedone sodium and tazobactam sodium and ratio of cefazedone sodium to tazobactam sodium |
| WO2018165048A1 (en) * | 2017-03-06 | 2018-09-13 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| US10125152B2 (en) | 2013-01-10 | 2018-11-13 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10214547B2 (en) | 2012-12-07 | 2019-02-26 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN109721618A (en) * | 2017-10-30 | 2019-05-07 | 刘力 | Cefpiramide noval chemical compound and combinations thereof and purposes |
| US10294248B2 (en) | 2013-03-14 | 2019-05-21 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10294247B2 (en) | 2014-06-11 | 2019-05-21 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10399996B2 (en) | 2015-09-11 | 2019-09-03 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10464952B2 (en) | 2015-12-10 | 2019-11-05 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10889600B2 (en) | 2016-08-04 | 2021-01-12 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| US11008346B2 (en) | 2014-06-11 | 2021-05-18 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US12173018B2 (en) | 2018-05-25 | 2024-12-24 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
-
2005
- 2005-11-17 CN CN 200510048556 patent/CN1965838A/en active Pending
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849947B (en) * | 2010-02-25 | 2012-07-04 | 深圳市新泰医药有限公司 | Composition of cefazedone sodium and tazobactam sodium and ratio of cefazedone sodium to tazobactam sodium |
| CN101838276A (en) * | 2010-05-17 | 2010-09-22 | 胡梨芳 | Cefpiramide sodium hydrate and preparation method and application thereof |
| WO2011144021A1 (en) * | 2010-05-17 | 2011-11-24 | 胡梨芳 | Cefpiramide sodium hydrate, preparation method and uses thereof |
| CN101838276B (en) * | 2010-05-17 | 2012-10-10 | 胡梨芳 | Cefpiramide sodium hydrate and preparation method and application thereof |
| CN102906100A (en) * | 2010-05-17 | 2013-01-30 | 胡梨芳 | Cefpiramide sodium hydrate, preparation method and uses thereof |
| CN101966152A (en) * | 2010-10-29 | 2011-02-09 | 广州白云山天心制药股份有限公司 | Cefpiramide composite |
| US10214547B2 (en) | 2012-12-07 | 2019-02-26 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10669290B2 (en) | 2012-12-07 | 2020-06-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10125152B2 (en) | 2013-01-10 | 2018-11-13 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US11414435B2 (en) | 2013-01-10 | 2022-08-16 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10294248B2 (en) | 2013-03-14 | 2019-05-21 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10294247B2 (en) | 2014-06-11 | 2019-05-21 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US11008346B2 (en) | 2014-06-11 | 2021-05-18 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10399996B2 (en) | 2015-09-11 | 2019-09-03 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US11046716B2 (en) | 2015-09-11 | 2021-06-29 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US10464952B2 (en) | 2015-12-10 | 2019-11-05 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US11560392B2 (en) | 2016-08-04 | 2023-01-24 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| US10889600B2 (en) | 2016-08-04 | 2021-01-12 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| WO2018165048A1 (en) * | 2017-03-06 | 2018-09-13 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| US11091505B2 (en) | 2017-03-06 | 2021-08-17 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| US11820784B2 (en) | 2017-03-06 | 2023-11-21 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| US12187752B2 (en) | 2017-03-06 | 2025-01-07 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| CN109721618A (en) * | 2017-10-30 | 2019-05-07 | 刘力 | Cefpiramide noval chemical compound and combinations thereof and purposes |
| US12173018B2 (en) | 2018-05-25 | 2024-12-24 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1965838A (en) | Pharmaceutical composition containing cefpiramide and beta-lactamase inhibitor | |
| CN101080221A (en) | Parenteral combination therpy for infective conditions with drug resistant bacterium | |
| JP2961182B2 (en) | Pharmaceutical composition for prevention and treatment of Clostridium difficile diarrhea and pseudomembranous colitis | |
| CN1513457A (en) | Anti beta-bactamase antibiotic compound prepn. | |
| CN103920137A (en) | Pharmaceutical composition having effect of resisting drug-tolerant gram positive bacteria | |
| CN101080230A (en) | Treatment and control of severe infections including cystic fibrosis | |
| Fisher et al. | Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli | |
| CN101574351A (en) | Cefmetazole preparation used for injection and preparation method thereof | |
| CN101849947B (en) | Composition of cefazedone sodium and tazobactam sodium and ratio of cefazedone sodium to tazobactam sodium | |
| CN1565457A (en) | Beta- lactamase suppressing antibacterial compound drugs | |
| RU2640928C2 (en) | Combination of fulvic acid and antibiotic for suppression of growth of bacteria resistant to majority of drugs, or treatment of infections caused by them | |
| CN1304725A (en) | Antibacterial cephalosporin composition | |
| CN1176657C (en) | Drug composition containing cefazolin and beta-lactamase inhibitor | |
| CN112999220B (en) | Application of alpha-lipoic acid as and/or preparing metallo-beta-lactamase inhibitor | |
| Sande | Antimicrobial therapy for two serious bacterial infections: enterococcal endocarditis and nosocomial pneumonia | |
| EP3733176B1 (en) | Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof | |
| CN1301110C (en) | Antimicrobial atresia with tauryl amine derivatives and carboxyl acid and/or its saltAnti | |
| CN1247200C (en) | Cefonicid sodium antibacterial composition | |
| CN1843354A (en) | Injectable pharmaceutical composition containing faropenem | |
| WO1995033463A2 (en) | Synergistic antibiotic compositions containing a perphyrin and an antibiotic | |
| Ma et al. | First isolation and identification of Shewanella xiamenensis from diseased Nile tilapia (Oreochromis niloticus L.) | |
| US4500516A (en) | Antibacterial pharmaceutical composition | |
| CN1526397A (en) | Combined antibiotic medicine for inhibiting beta-lactamase | |
| RU2424801C1 (en) | Medication for treatment of infectios diseases | |
| Rao et al. | Cephalosporin Antibiotics History and Update |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |